司美格鲁肽去年卖了2508亿元

Core Viewpoint - Novo Nordisk's flagship product, semaglutide, achieved a total sales revenue of 228.29 billion Danish Krone (approximately 250.84 billion yuan) in 2025, marking a growth of over 10% year-on-year [3]. Group 1: Product Performance - The sales breakdown for semaglutide includes: - Ozempic (diabetes version) with sales of 127.09 billion Danish Krone - Wegovy (weight loss version) with sales of 79.11 billion Danish Krone - Oral semaglutide (diabetes version) with sales of 22.09 billion Danish Krone [3]. - In the Chinese market, the total sales for the three series of semaglutide products reached 6.81 billion Danish Krone (approximately 7.49 billion yuan) [4]. Group 2: Financial Overview - Novo Nordisk's overall revenue for the year was 309.06 billion Danish Krone, reflecting a year-on-year growth of 6%, and a growth of 10% when adjusted for constant exchange rates [5]. - The net profit for the company was 102.43 billion Danish Krone, showing a year-on-year increase of 1% [5]. Group 3: Challenges and Market Dynamics - 2026 poses significant challenges for Novo Nordisk as the core compound patent for semaglutide will expire in some international markets, including China on March 20, 2026, leading to potential price competition from generic drugs [5]. - There are currently 10 applications for semaglutide generics filed in the Chinese market, with an additional 11 in Phase III clinical trials [6]. Group 4: Strategic Responses - In response to the patent expiration, Novo Nordisk plans to launch an oral GLP-1 weight loss drug, Wegovy tablets, which received approval in the U.S. in December 2025 and was launched on January 5, 2026, with a weekly prescription volume of approximately 50,000 as of January 23, 2026 [6][7]. - The company is also working on a stronger weight loss GLP-1 drug, having submitted new drug applications for a 7.2 mg semaglutide injection and CagriSema, a combination of cagrilintide and semaglutide, which showed a weight loss of 22.7% over 68 weeks in trials [7]. Group 5: Market Outlook - The global GLP-1 market is expected to continue expanding, and Novo Nordisk's new therapies aim to broaden patient coverage and increase sales [8].